Patients with Non-response to Neoadjuvant Chemoradiation for Esophageal Cancer Have No Survival Advantage over Patients Undergoing Primary Esophagectomy.

Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
Guillaume S ChevrollierAdam C Berger

Abstract

Survival for patients with locally advanced esophageal cancer remains dismal. Non-response to neoadjuvant chemoradiation (nCRT) portends worse survival. We hypothesized that patients undergoing up-front esophagectomy may have better survival than those who do not respond to nCRT. We identified all patients undergoing esophagectomy with a pathologic stage of II or greater at our institution between 1994 and 2015 and separated them into two groups: those who received nCRT and those undergoing up-front esophagectomy. The neoadjuvant group was further separated into patients downstaged to pathologic stage 0 or I (responders) and patients with either the same or higher pathologic stage after nCRT, or with pathologic stage II disease or greater (non-responders). Overall survival was compared between groups using Kaplan-Meier statistics. Covariate-adjusted Cox modeling was used to estimate hazard ratios (HR) for mortality associated with non-response. Overall, 287 patients met inclusion criteria. Fifty-nine percent of the responders had pathologic complete response (pCR). The majority of non-responders and primary esophagectomy patients had stage II or III disease (94%). Median survival was 58.3 months in responders, 23.9 months in no...Continue Reading

References

Aug 15, 1996·The New England Journal of Medicine·T N WalshT P Hennessy
Mar 23, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adam C BergerMelvyn Goldberg
Aug 29, 2006·The Journal of Thoracic and Cardiovascular Surgery·John V ReynoldsPatrick Byrne
Mar 3, 2007·The Lancet Oncology·Val GebskiUNKNOWN Australasian Gastro-Intestinal Trials Group
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel TepperRobert Mayer
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael StahlHansjochen Wilke
Dec 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthias SchauerJoerg Theisen
Jun 21, 2011·The Lancet Oncology·Katrin M SjoquistUNKNOWN Australasian Gastro-Intestinal Trials Group
Sep 29, 2011·The Annals of Thoracic Surgery·Robert E MerrittJoseph B Shrager
Jun 1, 2012·The New England Journal of Medicine·P van HagenUNKNOWN CROSS Group
Jul 2, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christophe MarietteJean-François Seitz
Jan 20, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F KlevebroM Nilsson
Feb 13, 2016·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·Yusuke SatoYoshihiro Minamiya
Feb 2, 2017·Journal of the American College of Surgeons·Emmanuel GabrielMoshim Kukar
Apr 5, 2017·Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus·Z Zhang, H Zhang
Jun 1, 2017·The New England Journal of Medicine·Norikazu MasudaMasakazu Toi
Aug 18, 2017·Journal of Thoracic Disease·Chantal M den BakkerDonald L van der Peet
Jul 19, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Jaffer A AjaniLenora A Pluchino

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.